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HIV patients stable on ART retain 
evidence of a high CMV load but changes 
to Natural Killer cell phenotypes reflect both HIV 
and CMV
Jacquita S. Affandi1, Jacinta Montgomery1, Silvia Lee1,2 and Patricia Price3*
Abstract 
Background: Whilst ART corrects many effects of HIV disease, T cell populations retain features of accelerated immu-
nological aging.
Methods: Here we analyse phenotypic changes to natural killer (NK) cells in HIV patients who began ART with <200 
CD4 T-cells/µl and maintained virological control for 12–17 years, compared with CMV seropositive and seronegative 
healthy control donors.
Results: Humoral responses to CMV antigens (lysate, gB, IE-1) remain elevated in the patients (P < 0.0001) despite the 
long duration of ART. Patient’s NK cells responded poorly to K562 cells when assessed by CD107a and IFNγ, but this 
could not be attributed to CMV as responses were low in CMV-seronegative controls. Moreover HIV (and not CMV) 
increased expression of CD57 on CD56lo cells.
Conclusions: Comparisons with published studies suggest that CMV accelerates age-related increases in CD57 
expression but levels plateau by 60–70 years of age, so the effect of CMV disappears. In HIV patients the plateau is 
higher and perhaps reached sooner.
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Background
Over 50  % of healthy individuals and 90  % of individu-
als living with HIV are seropositive for cytomegalovirus 
(CMV). Retinitis is the most common manifestation of 
CMV disease in human immunodeficiency virus-1 (HIV) 
-infected individuals, affecting up to 40  % of American 
acquired immune deficiency syndrome (AIDS) patients 
[1], and 5–25 % of HIV patients in the developing world 
[2]. As CMV prophylaxis is expensive, it is suspended 
once patients are stable on antiretroviral therapy (ART). 
However CMV establishes latency with frequent reacti-
vation triggered by inflammatory mediators, including 
tumour necrosis factor (TNF) [3]. Immune activation 
persists in HIV patients responding to ART [4] and levels 
of TNFα remain elevated (e.g. [5]), so subclinical reacti-
vations of CMV triggered by these factors may continue 
on ART [3]. Indeed titres of antibody reactive with CMV 
increase in the first year on ART. They decline thereaf-
ter but remain above those seen in age-matched healthy 
controls. This cannot be explained by hypergammaglob-
ulinaemia [6] and likely reflects a high burden of CMV 
persisting on ART.
Associations between CMV replication and cardio-
vascular disease include studies of clinical material link-
ing atherosclerosis with induction of adhesion molecules 
in endothelial tissues actively infected with CMV [7]. 
This fits clinical evidence associating increased T-cell 
responses to CMV with more severe cardiovascular 
changes in HIV patients [8]. In addition, CMV drives 
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T-cells to replicative senescence. In older CMV-sero-
positive adults (not infected with HIV), up to 23 % of the 
T-cell population can be CMV-specific [9, 10]. CMV-spe-
cific T-cells carry an immunosenescent phenotype that 
includes expression of CD57 and limited proliferative 
potential. T-cell senescence can impair T-cell homeo-
stasis when thymic activity is depressed, as it is in HIV 
patients. Indeed T-cell expression of CD57 and an associ-
ated switch from interleukin (IL)-2 to interferon gamma 
(IFNγ) production are evident in HIV patients with a sta-
ble response to ART [11].
Several lines of evidence suggest that natural killer 
(NK) cells are important in the control of CMV. Direct 
evidence is provided by a congenitally T-cell deficient 
child whose acute CMV infection was accompanied by 
an expansion of NK cells which resolved with her plasma 
CMV-deoxyribonucleic acid (DNA) [12]. Teleological 
evidence also implicates NK cells. Human and mouse 
CMV diverged with their host species during mamma-
lian evolution but both encode host proteins able to sub-
vert NK-mediated killing [13]. In HIV patients, NK cells 
also retain the imprint of the pre-ART immune system 
for many years. For example after 8 years on ART, IFNγ 
responses of CD4 T-cells to CMV were inversely related 
to CD4 T-cell counts before ART in patients who began 
ART with <60 CD4 T-cells/μL, but IFNγ responses of NK 
cells to a target cell lacking ligands for inhibitory recep-
tors (K562 cells) were directly proportional to nadir CD4 
T-cell counts [14]. NK cell IFNγ responses remained 
lower than in controls, confirming persistent NK dys-
function [15].
Here we address whether phenotypic profiles of NK 
cells in HIV patients stable on ART remain abnormal and 
reflect the immunological “footprint” of CMV. For this 
purpose, the lifetime burden of CMV is estimated from 
the levels of antibodies reactive with CMV lysate, glyco-
protein B (gB) protein or immediate early (IE)-1 antigen, 
or CD4 T-cell IFNγ responses.
Leukocyte immunoglobulin-like receptor-1 [LIR-1 
(ILT2, LIRB1, CD85j)] expression was proposed as an 
early marker of CMV replication in transplant recipients, 
as its expression is increased before CMV-DNA appeared 
in plasma [16, 17]. Increased expression of LIR-1 on 
NK cells was associated with atherosclerosis [18], con-
sistent with a role for CMV in atherogenesis. CD57 
expression by NK cells marks terminal differentiation. 
CD57+CD56loNKG2C+ NK cells have poor proliferative 
capacity and are enriched in organ transplant patients 
with active CMV infections [19, 20]. Our study describes 
HIV patients who began ART with <200 CD4 T-cells/µl 
and maintained virological control for 12–17  years. We 
selected this narrow demographic band as it remains 
the best long-term outcome for patients beginning ART 
with advanced HIV disease. It is pertinent to establish the 
benefits that they may accrue from CMV therapy.
Results
Humoral responses to all CMV antigens remain elevated 
in HIV patients stable on ART
All HIV patients had begun ART with low CD4 T-cell 
counts and achieved significant immune reconstitution 
[median (interquartile range): nadir 42 (23–142) CD4 
T-cells/µl and current 691 (576–889) CD4 T-cells/µl after 
174 (165–185) months on ART]. HIV patients and CMV 
seropositive (CMV+) healthy controls were similar in 
age, but the CMV seronegative (CMV−) controls were a 
little younger (Table 1).
Levels of antibodies reactive with CMV lysate, CMV gB 
and CMV IE1 were higher in HIV patients than CMV+ 
controls. In HIV patients, levels of antibodies reactive 
with CMV antigens were tightly correlated (R  =  0.57–
0.81, P = 0.009 to <0.0001). The relationship was similar 
in CMV+ controls (R =  0.52–0.57, P =  0.02–0.18) and 
levels of antibody reactive with lysate and gB were cor-
related in CMV− controls (R  =  0.75, P  =  0.025), con-
sistent with everyone having some exposure to CMV in 
their lifetime. Antibody levels were not influenced by age, 
perhaps because the age range was limited (50–73 years). 
Antibody levels in HIV patients were steady or declined 
marginally on ART (R = −0.34 to −0.05, P = 0.14–0.85).
Compared with the clear difference in humoral 
responses to CMV, CD4 T-cell IFNγ responses to CMV 
lysate did not differ between HIV+ CMV+ patients and 
CMV+ controls (P = 0.16). However IFNγ and antibody 
responses to CMV lysate were suggestive of associa-
tion in CMV+ controls (R = 0.44, P = 0.08), but not in 
patients (R =  0.25, P =  0.29). From these comparisons, 
we selected antibody titres rather than IFNγ responses to 
assess the footprint of CMV on NK cells in HIV patients.
NK cell function is depressed by stably treated HIV disease, 
without the boost to NK function attributed to CMV 
in controls
HIV patients had higher proportions of CD8 T-cells 
and slightly lower proportions of NK cells than CMV+ 
or CMV− controls individually (Table  1), with signifi-
cantly less NK cells than the combined control groups 
(P = 0.03). Whilst the proportions of CD56lo and CD56hi 
cells did not differ between groups, the CD56hi/CD56lo 
ratio was slightly higher in CMV− controls (P = 0.01 and 
P = 0.06 vs HIV patients and CMV+ control resp). These 
differences are not considered clinically informative.
NK cell function was then assessed from the propor-
tion of NK cells expressing CD107a or IFNγ with and 
without stimulation with K562 cells. These markers were 
predominantly expressed on CD56lo NK cells (Additional 
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file  1: Figure  S1) and their expression was invariably 
increased by culture with K562 cells. After stimulation 
with K562 cells, expression of CD107a and IFNγ by NK 
cells was lower in HIV patients than in CMV + controls 
(Table  1). Moreover NK IFNγ responses were lower in 
HIV patients who had been on ART for longer periods 
(R  =  −0.60, P  =  0.01), with CD107a following a simi-
lar trend (R = −0.34, P = 0.15). IFNγ production gated 
specifically to CD56hi NK cells was not increased by 
K562 cells in any group (P = 0.46–0.96; data not shown), 
but followed a pattern similar to that seen with CD56lo 
NK cells. Specifically, expression in unstimulated cul-
tures from HIV patients was slightly lower than from 
CMV + controls and was inversely proportional to time 
on ART (R = −0.41, P = 0.09).
CD107a responses were lowest in CMV- controls, 
so the low NK responses of HIV patients occur despite 
their greater humoral responses to CMV. Indeed HIV 
patients displayed variable but always negative correla-
tions between CD107a expression (±K562 cells) and 
CMV antibody (lysate, gB, IE-1; R  =  −0.11 to −0.48). 
IFNγ production by CD56lo or CD56hi NK cells did not 
correlate consistently with levels of CMV antibody in any 
group of donors (R = −0.58 to 0.33).
LIR‑1 expression was not related to levels of CMV antibody, 
but associated with CD107a responses in HIV patients
The expression of LIR-1 on NK cells and CD8 T-cells was 
similar in CMV+ HIV patients and control donors, and 
slightly lower in CMV− controls. This trend was evident 
when LIR-1+ cells were assessed as a percentage of NK 
cells or CD8 T-cells (data not shown) or by the median 
fluorescent intensity (MFI) of LIR-1 (Table 1; Additional 
file 1: Figure S1), but did not reach statistical significance. 
Levels of antibody reactive with CMV did not correlate 
with the MFI of LIR-1 on NK cells or CD8 T-cells in HIV 
patients (R  =  −0.38 to 0.06) or CMV+ (R  =  −0.17 to 
0.49) or CMV− (R = −0.40 to −0.10) controls.
LIR-1 is an inhibitory receptor but its ligand [human 
leukocyte antigen-G (HLA-G)] is not found on K562 
cells [21], so correlations between LIR-1 expression and 
NK responses to this target are indirect. In HIV patients, 
NK expression of CD107a correlated with expression of 
LIR-1 on NK cells (Table 2) and CD8 T-cells (P = 0.05, 
Table 1 HIV patients stable on ART retain high titres of CMV reactive antibodies, with NK cell phenotypes and function 
affected by HIV and CMV status
a Median (interquartile range)
b Mann–Whitney tests (continuous data), P ≤ 0.05 (bold), P > 0.05–0.1 (italics)
c Fisher’s exact test (categorical data)
d Cultured without K562 cells
e IFNγ spots per 2 × 106 cells
HIV patients CMV+ controls CMV− controls A vs B A vs C B vs C
A B C Pb Pb Pb
n 20 16 9
Male:female 19:1 14:2 9:0 0.57c 1 0.52
Age (years) 62 (57–68)a 60 (57–62) 55 (53–59) 0.19 0.04 0.11
CMV lysate IgG (AU/ml) 94 (56–240) 20 (10–35) 0.9 (0.6–1.0) <0.0001 <0.0001 <0.0001
CMV gB IgG (AU/ml) 127 (90–172) 45 (27–55) 1.9 (1.1–2.8) <0.0001 <0.0001 0.0001
CMV IE–1 IgG (AU/ml) 49 (21–166) 8 (4.3–180) 2.6 (2.0–3.7) <0.0001 <0.0001 0.0017
CMV lysate IFNγe 227 (16–700) 157 (13–617) 0 (0–0.5) 0.16 <0.0001 <0.0001
NK cells (% lymphocytes) 12 (8.3–18) 17 (11–20) 17 (12–22) 0.09 0.07 0.76
CD8 T-cells (% lymphocytes) 39 (19–48) 17 (7–23) 13 (10–19) 0.0007 0.001 0.71
CD56hi/CD56lo ratio × 100 7.2 (3.5–18) 7 (2.5–9.8) 12 (9.0–26) 0.51 0.01 0.06
IFNγ+ (% NK cells)d 0.2 (0.1–0.32) 0.1 (0.1–0.38) 0.4 (0.15–0.55) 0.93 0.19 0.17
IFNγ+ (% NK cells) + K562 0.8 (0.3–1.10) 1.7 (1.0–2.6) 1 (0.65–2.75) 0.006 0.21 0.4
CD56hiIFNγlo (% NK cells)d 0.36 (0.07–1.3) 1.1 (0.48–1.6) 0.4 (0.16–0.97) 0.08 0.96 0.12
CD107a+ (% NK cells)d 6.3 (2.6–8.6) 6.2 (4.6–7.9) 3.0 (2.2–6.0) 0.86 0.16 0.03
CD107a+ (% NK cells) + K562 11 (6.3–14) 16 (9.8–17) 8.4 (6.1–11) 0.03 0.48 0.006
LIR–1 MFI (NK cells) 554 (419–706) 524 (351–774) 301 (270–734) 0.82 0.27 0.17
LIR–1 MFI (CD8 T cells) 494 (385–679) 526 (429–852) 374 (283–807) 0.3 0.07 0.15
CD57+ (%NK cells) 77 (59–83) 64 (54–66) 63 (59–65) 0.02 0.09 0.98
CD56lo perforinhi (% NK cells)d 85 (76–90) 83 (77–89) 79 (70–87) 0.77 0.29 0.25
CD56hi perforinlo (% NK cells)d 3.0 (1.0–5.9) 3.1 (1.7–5.3) 5.2 (2.9–5.3) 0.88 0.07 0.08
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R =  0.45 unstimulated; P =  0.01, R =  0.55 with K562). 
CD107a responses did not correlate with expression 
of LIR-1 on NK cells (Table 2) or CD8 T-cells (P > 0.10; 
R  =  0.20–0.49) in CMV+ or CMV− controls, but this 
may reflect the smaller sample sizes. Correlations were 
also clearer in patients than CMV+ or CMV− controls 
when LIR-1+ cells were gated (data not shown).
CD57 expression was not related to levels of CMV 
antibody, but was increased and correlated with CD107a 
and perforin responses of CD56lo NK cells in HIV patients
CD57 was expressed on a higher proportion of NK cells 
from HIV patients than CMV+ controls (P  =  0.02). 
Expression was similar in CMV+ and CMV− controls, 
and was not proportional to levels of CMV antibody 
in HIV patients (P  =  0.22–0.57, R  =  −0.13 to −0.29). 
Examination of the flow cytometry plots confirmed that 
CD57 was expressed on CD56lo NK cells in all donors 
(Additional file 1: Figure S1; [19]).
In HIV patients, CD57 expression on NK cells cor-
related directly with expression of CD107a, with a 
weak inverse association with IFNγ (±K562 cells). HIV 
patients also demonstrated a striking correlation between 
CD57 expression on NK cells and the CD56loPerforinhi 
phenotype. This was complemented by an inverse cor-
relation between CD57 and the CD56hiPerforinlo phe-
notype (Table  2). No associations were seen in control 
donors.
Discussion
The effects of HIV disease and ART on NK phenotypes 
are unclear. Azzoni et al. [21] describe low NK cell num-
bers and poor NK cell cytotoxicity during untreated HIV 
infection, with limited recovery over 1–2 years on ART. 
Goodier et  al. [22] reported that NK IFNγ responses 
remain low on ART despite in  vitro stimulation with 
IL-2, IL-12 and IL-15. However Alter et al. [23] demon-
strated increased IFNγ and CD107a responses per NK 
cell in viremic patients with resolution over 1  year on 
ART. The contribution of CMV to changes attributed to 
HIV may be critical and is addressed here.
Our study describes patients who began ART with 
<200 CD4 T-cells/µl and maintained virological control 
for 12-17  years. We confirmed that humoral responses 
to CMV antigens (lysate, gB, IE-1) remain elevated above 
levels seen in CMV-seropositive controls (P  <  0.0001) 
and linked this with T-cell senescence and low nadir CD4 
T-cell counts [24]. Patients had slightly lower proportions 
of NK cells but their ratios of CD56hi/CD56lo cells were 
similar to controls.
We then assessed the functional capacity of NK cells 
using IFNγ and expression of CD107a by NK cells. 
IFNγ is produced when NK cells become activated [25], 
whereas CD107a lines the membrane of cytolytic gran-
ules and is detected when the granule fuses with the cell 
membrane [26]. HIV patients responded poorly to K562 
cells when assessed by CD107a and IFNγ on CD57lo NK 
cells, but this could not be attributed to their burden of 
CMV as responses were lowest in CMV-seronegative 
controls. In contrast, HIV patients described by Lima 
et  al. [27] displayed normal to elevated NK responses 
to phorbol myristate acetate (PMA)/calcium (Ca) iono-
phore. This may reflect the means of stimulation, as 
PMA/Ca ionophore bypasses the NKG2D-mediated 
mechanisms invoked by K562 cells [28].
LIR-1 has been proposed as a measure of the “footprint” 
of CMV as its expression is increased on NK cells from 
CMV-seropositive individuals [16–18]. LIR-1 expres-
sion on NK cells has not been monitored during HIV 
infection but LIR-1 is implicated in the control of HIV 
Table 2 In HIV patients, NK expression of  CD57 correlated directly with  CD107a+ and  perforinhi expression on  CD56lo 
cells and inversely with IFNγ responses and the CD56hi perforinlo phenotype
a Spearman’s correlation test , P < 0.05 (bold), P > 0.05–0.1 (italics)
Population assessed as % NK cells expressing…. HIV patients CMV+ controls CMV− Controls
Pa Ra P R P R
LIR-1 (MFI on NK cells) vs….
 CD107a 0.01 0.56 0.15 0.38 0.49 0.26
 CD107a with K562 0.02 0.31 0.26 0.31 0.23 0.45
CD57 vs….
 CD107a 0.02 0.56 0.73 0.09 0.43 −0.3
 CD107a with K562 0.08 0.40 0.28 −0.30 0.70 0.15
 IFNγ 0.10 −0.41 0.06 −0.48 0.61 −0.2
 IFNγ with K562 0.14 −0.35 0.09 −0.44 0.17 0.5
 CD56loperforinhi 0.001 0.72 0.28 0.29 0.49 0.27
 CD56hiperforinlo 0.004 −0.64 0.86 0.05 0.64 0.23
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replication [29]. Here expression of LIR-1 was marginally 
lower in CMV seronegative controls, but was not affected 
by HIV or proportional to levels of CMV antibody in any 
group. Whilst this precludes its use as a measure of the 
CMV footprint in this setting, we noted a relationship 
between LIR-1 and CD107a expression in HIV patients. 
This probably means that LIR-1 expression is a property 
of NK cells that are healthy enough to kill, as LIR-1 is an 
inhibitory receptor and is not implicated in the killing of 
K562 cells since they don’t express HLA-G [28].
CD57 has been proposed as a marker of “memory” 
NK cells that have been expanded in response to CMV, 
as NK cells co-expressing the activating NKG2C recep-
tor and CD57 are expanded by CMV seropositivity in 
healthy college students, but not by active infection with 
Epstein-Barr virus (EBV) [30]. Here HIV (and not CMV) 
increased the expression of CD57 on CD56lo cells. This 
was also seen in a mixed cohort of viraemic and avirae-
mic HIV patients (n = 13), where patients displayed 40 % 
CD57+ NK cells vs 20 % in controls. CD57 expression cor-
related with levels of CMV antibodies in each group [30], 
which was not evident in our study. However the patients 
and controls had a broad range of ages (25–66 years). A 
recent study [31] showed expression of CD57 increased 
with age from ~50 % of CD56lo NK cells in CMV+ donors 
aged under 35  years to 65–70  % in those >70  years old. 
CMV-seronegative younger donors had just 30–35  % 
CD57+ NK cells. This is consistent with our data as our 
control donors (CMV+ and CMV−) were 50–70  years 
old with ~64 % CD57+ NK cells. It makes our finding that 
77(59–83) % of NK cells from HIV patients express CD57 
all the more striking. We conclude that CMV accelerates 
age-related increases in CD57 expression but levels pla-
teau by 60–70 years of age. In HIV patients the plateau is 
higher and perhaps reached sooner.
Overall, the effects of HIV disease on NK cells in 
patients stably controlled on ART were most clearly 
marked by expression of CD57. Elevated expression of 
CD57 on NK cells from HIV patients is likely to have 
functional consequences as it correlated directly with 
CD107a and perforin by CD56lo cells and inversely with 
IFNγ responses and the CD56hi perforinlo phenotype. 
In this older and stably treated patient cohort, CD57 
expression was not proportional to the burden of CMV 
as measured by levels of antibody. The inclusion of rare 
CMV-seronegative HIV patients and parallel sensitive 
assessments of CMV DNA are needed to define the roles 
of CMV and HIV in NK dysfunction.
Methods
Patients and controls
Twenty CMV-seropositive HIV patients were recruited 
at Royal Perth Hospital, Western Australia, on the basis 
of being >50  years old with nadir CD4 T-cell counts 
<200 cells/µl, with >10 years on ART and >1 year of com-
plete viral suppression (<50 HIV RNA copies/ml). ART 
comprised at least three antiretroviral drugs. Sixteen 
CMV-seropositive healthy controls (CMV+) and nine 
male CMV-seronegative healthy controls (CMV−) were 
included. All donors were Caucasian. CMV seropositiv-
ity in patients and controls was defined as >1100  AU/
mL CMV lysate antibody, where the cut-off was based on 
eleven samples from persons negative by routine serol-
ogy and detection of CMV DNA (Abbott, Lake Forrest, 
IL, USA). Informed consent was obtained from all par-
ticipants in accordance with approvals from Royal Perth 
Hospital.
Sample collection and storage
Peripheral blood mononuclear cells (PBMC) were iso-
lated by ficoll density gradient centrifugation (Ficoll-
Paque Plus; GE Healthcare Biosciences, Sweden). 
2.0 × 106 cells were set aside for flow cytometry, whilst 
remaining cells were resuspended at 10 ×  106 cells/mL 
in fetal calf serum (FCS) with 10  % dimethyl sulfoxide 
(DMSO) for storage in liquid nitrogen.
CMV antibody and IFNγ responses
IgG reactive with CMV was quantitated using CMV 
lysate, CMV gB and CMV IE-1 antigens. CMV lysate was 
prepared by sonication of human foreskin fibroblasts 
(HFF) infected with CMV strain AD169. Uninfected HFF 
were prepared and extracts were run in parallel. Repli-
cate ELISA plates were coated with CMV gB (2800-800 
produced in hamster ovary cells, Chiron Diagnostics, 
Medfield, MA, USA; 50  ng/mL) and CMV IE-1 (130-
092-137, produced in E.coli; Miltenyi Biotech, Bergisch 
Gladbach, Germany; 2500 ng/mL). Plasma samples were 
diluted from 1:200. Binding was detected using goat anti-
human IgG conjugated horse radish peroxidase (HRP), 
followed by tetramethylbenzidine (TMB) substrate 
(Sigma-Aldrich; St Louis, MI, USA). Four-parameter 
logistic standard curves were generated from titrations of 
a plasma sample assigned a value of 1100 arbitrary units 
(AU) IgG reactive with each and unit values were derived 
for all samples. Units of antibody detected on plates 
coated with uninfected HFF were subtracted from those 
generated using CMV-coated plates. IFNγ responses of 
CD4 T-cells were assessed by ELISpot assay as described 
previously [11].
NK cell and T cell phenotypes assessed ex vivo by flow 
cytometry
Fresh PBMC (0.5 × 106 cell per tube) were resuspended 
in 20 μl phosphate buffered saline (PBS) with 1 % bovine 
serum albumin (BSA) and antibodies were added for 
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15  min (room temperature). This included PE-ILT2 
(LIR-1) clone GHI/75 (Biolegend San Diego, CA, USA), 
APC-CD57 clone NK-1, PerCP-Cy5.5-CD3 clone SK7, 
V450-CD56 clone B159, V500-CD8 clone RPA T8 (BD 
Biosciences, San Jose, CA, USA). 250,000 events were 
acquired using a FACS Canto II cytometer (BD Bio-
sciences) and analyzed with FlowJo software (Tree Star, 
San Carlos, CA, USA). Gating strategies are illustrated in 
Additional file 1: Figure S1.
Assessment of NK function
K562 cells were propagated in RPMI/10  % FCS and 
sub-cultured 24  h before use. Cryopreserved PBMC 
were washed in RPMI and cultured in RPMI/5  % FCS 
at 1  ×  106 cells/mL with K562 cells at a target:effector 
ratio of 10:1. After 6 h (37  °C), cells were transferred to 
flow tubes in PBS/1 %BSA, washed and 10 μL FcR Block 
(Miltenyi Biotech) was added for 20  min (4  °C). Cells 
were stained for extracellular markers [PerCP-Cy5.5-
CD3, V450-CD56, V500-CD8, APC-CD107a clone 
H4A3] (BD Biosciences) for 15 min (room temperature). 
They were then washed, 250  μL Cytofix/Cytoperm (BD 
Biosciences) was added for 20  min (4  °C), followed by 
antibodies reactive with intracellular markers [FITC-per-
forin clone γG9; PE-IFNγ clone 4S.B3] (BD Biosciences) 
for 30  min. Washed cells were resuspended in PBS/1  % 
BSA and 500,000 events were acquired and analyzed 
(Additional file 1: Figure S1).
Statistical analysis
Results were presented as median (interquartile range) 
unless otherwise stated. Bivariate analyses were based on 
Mann–Whitney tests or Fisher’s test as indicated in the 
Table 1. Correlation coefficients were determined by the 
Spearman’s Rank Correlation Test (GraphPad Prism ver-
sion 5 for Windows, GraphPad Software, La Jolla, CA, 
USA). For all tests, P < 0.05 was considered to represent 
a significant difference and highlighted in bold, whereas 
0.05 < P < 1 is italicized.
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Tumour necrosis factor.
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